Bizarre Patents
A method for inducing cats to exercise consists of directing a beam of invisible light produced by a hand-held laser apparatus onto the floor or wall.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8148362 | Compound having heterocyclic ring The invention provides a novel oxazolidinone derivative represented by the formula (I): wherein Ring A is optionally substituted or fused and represents (A... | 04/03/2012 |
| 8138168 | Renin inhibitors The invention relates to compounds having the formulae: wherein the variables are as defined herein. The invention further relates to methods of making and using these compounds, and pharmaceutical compositions, kits and ar... | 03/20/2012 |
| 8114865 | Indazole derivatives as kinase inhibitors for the treatment of cancer Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful ... | 02/14/2012 |
| 8076321 | Compositions for treatment of systemic mastocytosis The present invention relates to the use of the combination of tyrosine phosphate inhibitors AMN107 and PKC412 for the preparation of a drug for the treatment of a mast cell-related proliferative disease. The present invention is also drawn to a combination treatmen... | 12/13/2011 |
| 8076320 | Crystalline forms of a pharmaceutical compound Described are crystalline forms of the pharmaceutical compound “[9S-(9α,10β,12α)]-5,16-Bis[(ethylthio)methyl]-2,3,9,10,11,12-hexahydro-10-hydroxy-9-methyl-1-oxo-9, 12-epoxy-1H-diindolo[1,2,3-fg:3′,2′,1′-kl]pyrrolo[3,4-i][1,6]benzodiazocine-10-carboxylic a... | 12/13/2011 |
| 8071587 | (Dihydro)imidazoiso[5,1-A]quinolines The invention relates to imidazoiso[5,1-a]quinoline and 5,6-dihydro-imidazoiso[5,1-a]quinoline derivatives according to general Formula I or a pharmaceutically acceptable salt thereof. The compounds can be used for the trea... | 12/06/2011 |
| 8039459 | Nicotinic receptor agonists for the treatment of inflammatory diseases Nicotine receptor agonists or analogs or derivatives thereof for treating inflammatory pulmonary diseases, and pharmaceutical compositions including nicotine receptor agonists or analogs or derivatives thereof. Compounds of formula wherein R1, R2, Xa and Ya are as d... | 10/18/2011 |
| 7973031 | Staurosporine derivatives as inhibitors of FLT3 receptor tyrosine kinase activity The present invention relates to the use of staurosporines derivatives for the preparation of a drug for the treatment of diseases involving deregulated FLT3 receptor tyrosine kinase activity, especially for the curative and/or prophylactic treatment of leukemias an... | 07/05/2011 |
| 7973032 | Staurosporine derivatives for use in alveolar rhabdomyosarcoma This invention relates to staurosporine derivatives are effective when used in combination with ionizing radiation for the delay of progression or treatment of a proliferative disease, especially a disease associated with a PAX/FKHR translocation including a PAX3/FK... | 07/05/2011 |
| 7902183 | Thiazolyl-dihydro-indazole The present invention encompasses compounds of general formula (1) wherein R1 to R5 are defined as in claim 1, which are suitable for the treatment of diseases characterized by exce... | 03/08/2011 |
| 7875605 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them N-arylsulfonyl-3-substituted indole compounds, derivatives, analogs, tautomeric forms, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts. ... | 01/25/2011 |
| 7834000 | CGRP receptor antagonists The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions. ... | 11/16/2010 |
| 7795246 | Particle-forming compositions containing fused pyrrolocarbazoles A non-aqueous, particle-forming, fused pyrrolocarbazole-containing composition is disclosed. Upon contact with an aqueous medium, the particle-forming composition spontaneously disperses into suspended particles, thereby forming a stable suspension that provides gre... | 09/14/2010 |
| 7786106 | Substituted benzene derivatives or salts thereof There are provided compounds having an anticoagulant action on the basis of inhibition of activated blood coagulation factor X and being useful as anticoagulants or preventive/therapeutic agents for diseases induced by thrombosis or embolism. Effective ingredients a... | 08/31/2010 |
| 7560450 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions The present invention relates to substituted xanthines of general formula the tautomers, the stereoisomers, the mixtures thereof, the prodrugs thereof and the salts thereof, which have valuable pharmacological properties, p... | 07/14/2009 |
| 7407949 | Benzamide derivatives as oxytocin agonists and vasopressin antagonists Novel compounds according to general formula 1, wherein G1 is NR5R6 or a fused polycyclic group that are specific OT receptor agonists and/or V1a receptor antagonists. Pharmaceutical compositions comprising such compounds ... | 08/05/2008 |
| 7358239 | Pyrrolidinyl, piperidinyl or homopiperidinyl substituted (benzodioxan, benzofuran or benzopyran) derivatives The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharmaceutically acceptable acid addition salt thereof, wherein -Z1-Z2- is... | 04/15/2008 |
| 7355069 | Ortho-substituted benzoic acid derivatives for the treatment of insulin resistance The present invention provides a compound of formula (I), wherein n is 0, 1 or 2 and R1 represents halo, a C1-4alkyl group which is optionally substituted by one or more fluoro, a C1-4alkoxy group which is optionally substituted by o... | 04/08/2008 |
| 7342006 | Substituted 8-heteroaryl xanthines Selective antagonists of A2B adenosine receptors like those of formula I are provide. The compounds and compositions are useful as pharmaceutical agents. ... | 03/11/2008 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7253157 | Polyarylcarboxamides useful as lipid lowering agents Polyarylcarboxamide compounds of formula (I) are useful as lipid lowering agents. ... | 08/07/2007 |
| 7238684 | Benzothiadiazepine derivatives, processes for their preparation and pharmaceutical compositions containing them The present invention relates to compounds of formula (I): wherein Rv, R1, R2, Rx, Ry, R3, R4, R5, R6, Rz and v are as defined within; pharmaceutically acce... | 07/03/2007 |
| 7232828 | PPAR Ligands that do not cause fluid retention, edema or congestive heart failure Methods are provided for treating or prophylactically preventing metabolic disorders in humans without causing, promoting, or aggravating fluid retention, peripheral edema, pulmonary edema, or congestive heart failure, by administration of a therapeutically effectiv... | 06/19/2007 |
| 7226937 | Methods for modulating phototoxicity The invention relates to methods for modulating photodamage via the use of collagen derived molecules which either enhance or inhibit damage caused by ultraviolet light. ... | 06/05/2007 |
| 7220742 | Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments The present invention relates to enantiomerically pure compounds of general formula 1 wherein the groups R1, R2, R3, R4 and X− may have the meanings given ... | 05/22/2007 |
| 7222176 | Apparatus and method for using storage domains for controlling data in storage area networks A Storage Domain architecture in which a pool of storage devices is controlled by one or a plurality of Storage Domain Servers (SDS) and create a single, compatible, enterprise wide, storage resource pool that appears to the system as a gigantic shared disk drive. T... | 05/22/2007 |
| RE39608 | Substituted benzimidazoles and their use as PARP inhibitors Compounds of the formula Ia or IB where A is a saturated or monounsaturated heterocyclic, 4 - to 8-membered ring which contains one or two nitrogen atoms, and their tautomeric forms, p... | 05/01/2007 |
| 7208487 | Compounds, compositions and methods Compounds useful for treating cellular proliferative diseases and disorders by modulating the activity of KSP are disclosed. ... | 04/24/2007 |
| 7183271 | 4,4-difluoro-1,2,3,4-tetrahydro-5h-1-benzazepine derivative or salt thereof A novel 4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepine derivative or a pharmaceutically acceptable salt thereof, which is useful as an agent for treating or preventing nocturia and/or diabetes insipidus, is provided. ... | 02/27/2007 |
| 7179920 | 3-thia-4-arylquinolin-2-one derivatives This invention describes compounds of Formula (I) which are modulators of potassium channels and are useful for treating conditions affected by abnormal potassium channel activity including erectile dysfunction and irritable bowel syndrome | 02/20/2007 |
| 7176195 | Fused azepine derivatives and their use as antidiuretic agents Compounds according to general formulae (1 and 2), wherein G1 is an azepine derivative and G2 is a group according to general formulae (9–11) are new. Compounds according to the invention are vasopressin V2 receptor agonists. Pharm... | 02/13/2007 |
| 7157584 | Benzimidazole derivative and use thereof The present invention relates to a compound represented by the formula (I) wherein R1 is a group represented by the formula wherein R2,... | 01/02/2007 |
| 7135473 | Cyclic diamine compound with condensed-ring groups A cyclic diamine compound of formula (1): wherein R1 and R2 are individually a hydrogen atom or a methoxy group, provided R1 is a methoxy group when R2 is a hydrogen at... | 11/14/2006 |
| 7132416 | Benzothiazepine and benzothiazepine derivatives with ileal bile acid transport (IBAT) inhibotory activity for the treatment hyperlipidaemia The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmaceutically ac... | 11/07/2006 |
| 7129239 | Purine compounds and uses thereof Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. ... | 10/31/2006 |
| 7081453 | Compounds for treating impaired fundic relaxation The present invention concerns compounds of formula (I) a stereochemically isomeric form thereof, an N-oxide form thereof or a pharma-ceutically acceptable acid addition salt thereof, wherein —a1═a2—a3═a4— is a b... | 07/25/2006 |
| 7064136 | Compounds A compound having the general formula and methods of using such compounds for the treatment of diseases and pharmaceutical composition comprising such compounds. ... | 06/20/2006 |
| 7056908 | Pharmaceutical compositions and methods for preventing skin tumor formation and causing regression of existing tumors Pharmaceutical compositions and methods for treating epithelial cancers and precancerous lesions employ indole carbazole compounds, such as staurosporine. Compositions containing these compounds are administered to a patient in an effective amount and may be adminis... | 06/06/2006 |
| 7056916 | Medicaments for the treatment of chronic obstructive pulmonary disease A pharmaceutical composition comprising a compound of formula 1 wherein: n is 1 or 2; R1 is hydrogen, C1–C4-alkyl, halogen, OH, or —O—C1... | 06/06/2006 |
| RE39112 | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine compound represented by the formula (I), its pharmacologically... | 05/30/2006 |
